News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Actinium Pharmaceuticals, Inc. (ATNM.OB) Engages A Leading CRO To Support Phase 3 Trial Of Iomab-B


6/16/2014 11:35:26 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK--(BUSINESS WIRE)--Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that it has executed an agreement with ACT Oncology, a full-service clinical research organization (CRO) specializing in providing oncology drug development support for biotech, pharmaceutical and non-profit oncology organizations, to utilize their services for a number of clinical development-related projects. This agreement includes the preparations for the Phase 3 clinical trial of Iomab-B, a myeloconditioning drug for bone marrow transplant preparation.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES